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Abstract
It has been proposed that human colorectal tumors
can be classified into two groups: one in which
methylation is rare, and another with methylation of
several loci associated with a ‘‘CpG island methylated
phenotype (CIMP),’’ characterized by preferential prox-
imal location in the colon, but otherwise poorly defined.
There is considerable overlap between this putative
methylator phenotype and the well-known mutator
phenotype associated with microsatellite instability
(MSI). We have examined hypermethylation of the
promoter region of five genes (DAPK, MGMT, hMLH1,
p16INK4a, and p14ARF) in 106 primary colorectal cancers.
A graph depicting the frequency of methylated loci in
the series of tumors showed a continuous, monotoni-
cally decreasing distribution quite different from the
previously claimed discontinuity. We observed a sig-
nificant association between the presence of three or
more methylated loci and the proximal location of the
tumors. However, if we remove from analysis the
tumors with hMLH1 methylation or those with MSI,
the significance vanishes, suggesting that the associ-
ation between multiple methylations and proximal
location was indirect due to the correlation with MSI.
Thus, our data do not support the independent
existence of the so-called methylator phenotype and
suggest that it rather may represent a statistical artifact
caused by confounding of associations.
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Introduction
Two different major pathogenetic mechanisms have been
proposed for the development of colorectal cancers (CRCs)
[1]. The first, so-called ‘‘classic pathway,’’ seems to be the
most common and depends on multiple additive mutational
events (germline and/or somatic) in tumor-suppressor
genes and oncogenes, frequently involving chromosomal
deletions in key genomic regions [2]. However, the ‘‘mutator
pathway,’’ operationally recognizable by the presence of
microsatellite instability (MSI), depends on early mutational
loss of the mismatch repair system (germline and/or somatic),
leading to accelerated accumulation of gene mutations in
critical target genes and progression to malignancy. The dis-
tinction between these pathways seems to be more than
academic because there is evidence that the tumors emerging
from the mutator pathway have a specific ‘‘mutator phenotype’’
that includes preferential localization in the right colon, undif-
ferentiated histology, lymphocyte infiltration, a better prognosis,
and resistance to adjuvant therapy with 5-fluorouracil [3–5].
Recently, it has been discovered that in either pathogenetic
pathways, loss of activity of key genes may occur through
epigenetic, rather than genetic, means [6]. Indeed, although
lack of expression of mismatch repair genes is generally found
in sporadic tumors with MSI, the majority of such tumors does
not show mutations in these DNA repair genes [7–9]. In fact,
methylation of hMLH1 is the single most common recognizable
form of MSI in sporadic colorectal tumors [10]. Recent work has
shown that loss of tumor-suppressor and/or DNA repair gene
function by promoter methylation can occur in many different
genes in sporadic CRCs [11]. In 1999, Toyota et al. studied
human CRC with a technique which they called ‘‘methylated
CpG island amplification’’ and observed that tumors could be
classified in two very distinct groups: one with simultaneous
methylation of several loci, and another in which methylation of
these loci was very rare. Moreover, they noted that a large
proportion of proximal tumors belonged to the former group,
and they proposed the existence of a ‘‘CpG island methylated
phenotype (CIMP).’’ They also observed that CIMP+ tumors
often also exhibited hMLH1 methylation and MSI, and they did
remark that MSI was also correlated with proximal tumors but
failed to point out that this chain of associations might lead to
confounding of variables [12].
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We have studied promoter methylation of the tumor-
suppressor genes p16INK4a and p14ARF, the apoptosis-
associated gene death–associated protein kinase (DAPK),
and the DNA repair genes hMLH1 and O6-methylguanine-
DNA-methyltransferase (MGMT), and also analyzed MSI in
106 human colorectal adenocarcinomas. We did not find
any discontinuities in the distribution of the number of meth-
ylated genes in CRC. Moreover, after we removed tumors
that had MSI from the statistical analysis, there was no
longer a significant association between multiple methylated
loci and proximal tumor location. Thus, our data do not sup-
port the existence of the so-called methylator phenotype
and suggest that it rather represents a statistical artifact
caused by confounding of associations.
Materials and Methods
Sample Collection and Nucleic Acid Isolation
Primary tumor samples from 106 patients diagnosed with
CRC were collected at the A. C. Camargo Cancer Hospital
(Sa˜o Paulo, Brazil). Informed consent was obtained from all
patients, and this research was approved by the Research
Ethics Committee of the A. C. Camargo Hospital and the
Ludwig Institute for Cancer Research (Sa˜o Paulo, Brazil).
In 30 of the patients, we also obtained matching normal
colon tissue. To avoid selection bias, the samples were
collected on sequential surgical cases of CRC. Immediately
after collection, the samples were snap-frozen in liquid
nitrogen and kept as part of a tumor bank. For this study,
H&E–stained sections from each tumor sample were histo-
logically examined, and only those that were microdissected
to contain more than 70% neoplastic cells were used for
analysis. DNA was prepared from microdissected tissue by
digestion with pronase in 1% SDS, followed by standard
phenol–chloroform extraction and ethanol precipitation [13].
In all patients, we obtained medical information on the na-
ture of the cancer, patient sex and age, tumor location, histo-
logic features, and clinical evolution.
Bisulfite Treatment and Methylation-Specific PCR (MSP)
MSP is based on the chemical modification of genomic
DNA with sodium bisulfite, which converts unmethylated
cytosines (but not methylated cytosines) to uracil. Specific
primers are then designed to distinguish between the se-
quence differences produced with methylated and unmeth-
ylated DNA inMSP [14]. We studied the methylation status of
the following loci: DAPK, MGMT, hMLH1, p16INK4a, and
p14ARF. Briefly, 1 mg of genomic DNA was denatured with
NaOH (final concentration, 0.2 M), and 10 mM 6-hydroqui-
none (Sigma, St. Louis, MO). Sodium bisulfite, pH 5.0
(Sigma), was added to a final concentration of 3 M and the
mixture was incubated at 50jC for 16 hours. The modified
DNA was then purified using the Wizard DNA purification kit
(Promega Corporation, Madison, WI), followed by precipita-
tion with ethanol.
The primers and thermal cycle conditions for MSP
of DAPK, MGMT, hMLH1, p16INK4a, and p14ARF were as
detailed elsewhere [14–17]. The PCR mixture contained
bisulfite-modified DNA, specific primers (final concentration,
0.6 mM each per reaction), 1 U of Taq polymerase (Pho-
neutria, Belo Horizonte, Brazil), and deoxynucleotide tri-
phosphates (1.25 mM) in 1% Triton X-100, 500 mM KCl,
15 mM MgCl2, and 100 mM Tris–HCl (pH 8.4). Reactions
were maintained at 950jC for 5 minutes before the addition
of polymerase. Amplification was carried out using a PTC100
MJ Research, Inc. Thermal Cycler (Watertown, MA). About
10 ml of the amplified products was electrophoresed on
6% acrylamide gels and visualized by silver staining.
MSI
The Bethesda consensus panel, composed of two mono-
nucleotide repeat microsatellites (BAT25 and BAT26) and
three dinucleotide repeat microsatellites (D2S123, D5S346,
and D17S250), was used to evaluate MSI [18]. The mono-
nucleotide microsatellite BAT-26, which is part of the panel,
has been reported to have close to 100% sensitivity and
specificity as a marker of this phenomenon [19,20]. As an
additional criterion for MSI, we also utilized a battery of nine
tetranucleotide microsatellite loci and one trinucleotide
microsatellite [21].
Statistical Analysis
The 2  2 cross-categorized frequency data were tested
by Fisher’s exact test using the online facility at http://
faculty.vassar.edu/lowry/VassarStats.html. A probability
value of < .05 was considered significant, and we applied
the Bonferroni correction for multiple comparisons [22].
Results
Frequency of Methylation in Primary Colorectal Tumors
and Corresponding Nonmalignant Tissues
We used MSP to determine the frequency of methylation
ofDAPK,MGMT, hMLH1, p16INK4a, and p14ARF in 106micro-
dissected primary CRCs. These loci were chosen because
they are among the most frequently methylated in CRC [23].
No aberrant methylation of any of these loci was detected in
30 samples of nonmalignant colon tissues. However, a total
of 109 methylation events was detected in 106 tumors. In
addition, the unmethylated form of all genes was detected in
100% of samples in both tumors and nonmalignant tissues.
This was not unexpected because, inevitably, all tumor
specimens contain a small proportion of normal cells. More-
over, some loci may be heterozygous for methylation and
thus possess a nonmethylated allele. As shown in Figure 1,
the most frequently methylated locus was MGMT (32/109;
29.4%), followed byDAPK (21/109; 19.3%), p16INK4a (20/109;
18.3%), hMLH1 (19/109; 17.4%), and p14ARF (17/109;
15.6%). We identified at least one methylated promoter
region in 58.5% (62/106) of the tumors (Figure 1). Overall,
41.5% (44/106) of the tumors had no methylated genes,
30.2% (32/106) had only one methylated gene, 16.0%
(17/106) had two methylated genes, 8.5% (9/106) had three
methylated genes, and 4% (4/106) had four methylated
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genes (Figure 2). We checked all loci for pairwise association
using Fisher’s exact test. The only significant association
found, following application of the Bonferroni correction for
multiple comparisons, was between the methylation of
p16INK4a and p14ARF. However, this finding was not pursued
further because numerous other studies have previously
tested the possibility of this association and ruled it out
[17,24,25].
MSI
We scored tumors for MSI (MSI+) following the Bethesda
guidelines [18] (i.e., if there were alterations in two or more
of the mononucleotide repeat microsatellites Bat25 and
Bat26, or the dinucleotide repeat microsatellites D2S123,
D5S346, and D17S250). As expected from previous reports
[19,20], deletions in the BAT26 were seen in all tumors with
instability. Moreover, we also looked for extra alleles in a
battery of one trinucleotide and nine tetranucleotide micro-
satellite loci [21]. There was complete concordance between
the two criteria. Fourteen of 106 tumors (13.2%) displayed
MSI. This value is compatible with that found in other studies
[26,27]. As expected, the presence of MSI was very highly
associated with the location of the tumor proximal to the
splenic flexure of the colon (Table 1). However, it showed no
significant correlation with recurrence within 3 years of
diagnosis (Table 1).
Association between Methylation and Clinical Features
We searched for associations between the number of loci
found to be methylated and some clinical characteristics of
the tumors (i.e., we tested if a ‘‘methylator phenotype’’ could
be recognized). Because we had not found any discon-
tinuities in the distribution of the number of methylated loci
per tumor (Figure 1) as previously claimed by Toyota et al.
[12,28], we lacked a clear criterion for defining a ‘‘high-
methylation group.’’ Thus, we did the analysis using as
‘‘high-methylation group’’ the category of three or moremeth-
ylated loci (criterion 1) and repeated it with the category of
two or more methylated loci (criterion 2). We used Fisher’s
exact test to assess, for each of the categories of z2 and
z3 methylated loci, an association with location of the tumor
(distal versus proximal colon), recurrence within 3 years of
diagnosis, and MSI. We found no significant association of
the level of methylation with recurrence rate or with MSI
(Table 1). However, tumor location was significantly asso-
ciated with three or more methylated loci (P = .011) and also
with two or more methylated loci (P = .029), although the for-
mer was no longer significant after applying the Bonferroni
correction for multiple comparisons (Table 1). This led us to
use Fisher’s exact test to ascertain whether there was
any association between location and methylation at each
of the five loci in isolation. There was no association of prox-
imal location with DAPK, MGMT, p14ARF, or p16INK4a, but
there was a highly significant association with themethylation
of hMHL1 that persisted after application of the Bonferroni
correction for multiple contrasts (Table 1). As expected,
methylation of hMLH1 was also highly associated with
MSI and with the categories of z2 and z3 methylated loci
(Table 1).
Discussion
CRC is a common malignancy that is expected to afflict
approximately 106,000 people and to cause 57,000 deaths in
the United States in 2004 [29]. There is an urgent need for
markers that can be used in the establishment of a prognosis
and that can guide in choosing the most appropriate treat-
ment. In this sense, the discovery of the ‘‘mutator pathway’’
of CRC, operationally signaled by the presence of MSI
(MSI+), was a major development. MSI+ CRC has charac-
teristic biologic properties that include preferential proximal
location, undifferentiated histology, and a relatively better
prognosis [3,4]. Recent data suggest that fluorouracil-based
adjuvant chemotherapy is of no benefit to patients with MSI+
CRC [5]. If these findings are confirmed, there will be a
strong case for testing all CRCs for MSI [30].
Hypermethylation of the promoter region of specific genes
can be profitably used as a molecular marker of cancer
cells in the detection of micrometastases, diagnosis of re-
currences, and even as a screening tool for discovering
primary tumors [6]. An advantage of DNA methylation is that
it constitutes a positive and stable marker that cannot be
masked by the presence of normal tissues and thus offers
Figure 1. Hypermethylation of the promoter region of five genes (DAPK, MGMT, hMLH1, p16INK4a, and p14ARF) in 106 microdissected primary CRCs. Each column
is a different tumor. Back squares indicate methylated loci. The top row shows (marked with an X) tumors with MSI (MSI+).
Figure 2. Bar graph of the proportion of methylated loci in 106 CRCs.
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extraordinary sensitivity in cancer detection through the use
of MSP. Moreover, methylation might provide a new thera-
peutic target in CRC [6]. It is less clear whether multiple
methylations have prognostic value. Toyota et al. [12,28]
proposed the existence of a ‘‘CIMP’’ in human CRC, which
included simultaneous methylation of several genes, prefer-
ential proximal location in the colon, and also an association
with MSI. Although several other authors have supported
this concept [31–33], the exact nature of such methylator
phenotype is still poorly defined [27]. In particular, there is
considerable overlap between the well-known phenotype
associated with MSI and the proposed methylator pheno-
type. Because there exists a correlation between multiple
methylations and MSI, the possibility of statistical confound-
ing must be considered.
We have examined here the hypermethylation of the
promoter region of five genes (DAPK, MGMT, hMLH1,
p16INK4a, and p14ARF) in 106 microdissected primary CRCs.
A histogram depicting the frequency of methylated loci in the
series of tumors showed a continuous, monotonically de-
creasing distribution (Figure 2) that was quite different from
the discontinuity that had been previously described by
Toyota et al. [12]. Our results agree well with other authors
who examined large numbers of tumors and who also did not
find any discontinuities [27,33]. There was a significant
association between the presence of three or more methyl-
ated loci and the tumor location proximal to the splenic
flexure (Table 1). However, if we removed from analysis
the tumors that display hMLH1 methylation or those with
MSI, the significance of association of ‘‘high methylation’’
with location vanishes (P = .32 and P = .26, respectively).
Likewise, the data of Yamashita et al. [27] also show that the
significant association observed between ‘‘high methylation’’
and right-side location becomes nonsignificant (after correc-
tion for multiple testing) on removal of the MSI+ tumors.
Thus, it appears that the association of ‘‘high methylation’’
with proximal location is not direct, but indirect, due to
correlation with MSI. However, the association of MSI with
location is known to occur very strongly in hereditary non-
polyposis colorectal cancer (HNPCC), in which 70% of
tumors are right-sided [3] and in which methylation is un-
common [10].
In conclusion, our data do not support the existence of a
methylator phenotype and suggest that it may represent a
statistical artifact caused by confounding with the phenotype
of tumors displaying MSI.
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